I-Semaglutide VS Tirzepatide

I-Semaglutide kunye ne-Tirzepatide zimbini amayeza amatsha asekelwe kwi-GLP-1 asetyenziselwa unyango lwe-2 yeswekile kunye nokukhuluphala.
I-Semaglutide ibonise iziphumo eziphezulu ekunciphiseni amanqanaba e-HbA1c kunye nokukhuthaza ukulahleka kwesisindo. I-Tirzepatide, inoveli emibini ye-GIP/GLP-1 i-receptor agonist, iphinde ivunywe yi-US FDA kunye ne-EMA yaseYurophu yonyango lwe-2 yeswekile.

Ukusebenza kakuhle
Bobabini i-semaglutide kunye ne-tirzepatide inokunciphisa kakhulu amanqanaba e-HbA1c kwizigulane ezinesifo sikashukela sohlobo lwe-2, ngaloo ndlela iphucula ulawulo lwe-glucose yegazi.

Ngokumalunga nokulahlekelwa kwesisindo, i-tirzepatide ibonisa ngokubanzi iziphumo ezingcono xa kuthelekiswa ne-semaglutide.

Umngcipheko weCardiovascular
I-Semaglutide ibonise izibonelelo ze-cardiovascular in the SUSTAIN-6 trial, kubandakanywa neengozi ezincitshisiweyo zokufa kwe-cardiovascular death, i-myocardial infarction engabulali, kunye ne-stroke engapheliyo.

Iziphumo zentliziyo ye-Tirzepatide zifuna uphononongo olongezelelweyo, ngakumbi iziphumo ezivela kulingo lwe-SURPASS-CVOT.

Ukuvunywa kweziyobisi
I-Semaglutide ivunyiwe njengenxalenye yokutya kunye nokuzivocavoca ukuphucula ulawulo lweswekile yegazi kubantu abadala abanesifo sikashukela sohlobo lwe-2, kunye nokunciphisa umngcipheko weziganeko ezinkulu zentliziyo kubantu abadala abanesifo sikashukela sohlobo lwe-2 kunye nesifo se-cardiovascular disease.

I-Tirzepatide ivunyiwe njengento edibeneyo yokutya okuncitshisiweyo kwekhalori kunye nokwandisa umsebenzi womzimba wokulawula ubunzima obungapheliyo kubantu abadala abanokukhuluphala okanye ukugqithisa kunye nobuncinci ubunzima obunxulumene nesisindo.

Ulawulo
Zombini i-semaglutide kunye ne-tirzepatide zilawulwa ngokuqhelekileyo ngenaliti engaphantsi kwe-subcutaneous.
I-Semaglutide nayo inokwakheka komlomo okukhoyo.